Palisade Bio (PALI) Income towards Parent Company (2010 - 2026)

Palisade Bio (PALI) has reported Income towards Parent Company for 17 consecutive years, with -$10.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Income towards Parent Company fell 365.12% year-over-year to -$10.7 million; the TTM figure through Mar 2026 stood at -$26.5 million (down 96.09% YoY), while the FY2025 annual figure was -$45.3 million, up 4.19% from the prior year.
• Income towards Parent Company retreated to -$10.7 million in Q1 2026 per PALI's latest filing, from -$10.0 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at -$2.3 million in Q1 2025 and bottomed at -$38.2 million in Q1 2023.
• Historically, Income towards Parent Company has averaged -$6.4 million across 5 years, with a median of -$3.7 million in 2024.
• Annual changes were most pronounced in 2023 — Income towards Parent Company sank 871.08% — and 2024, when it surged 90.34%.
• Palisade Bio's Income towards Parent Company stood at -$3.8 million in 2022, then increased by 17.97% to -$3.2 million in 2023, then slipped by 7.28% to -$3.4 million in 2024, then slumped by 194.75% to -$10.0 million in 2025, then decreased by 7.64% to -$10.7 million in 2026.
• Business Quant data shows PALI's Income towards Parent Company at -$10.7 million in Q1 2026, -$10.0 million in Q4 2025, and -$2.9 million in Q3 2025.